9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Estimated reading time: < 1 min

Condition: Advanced Malignant Mesothelioma

Estimated Enrollment: 55

Gender: All

Min Age:

Age Group: Child, Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Overall survival rate,  RECIST response rate,  Association between EGFR expression with survival and response,

Interventions: erlotinib hydrochloride, laboratory biomarker analysis

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2007

Completion Date:

Last  Posted Date: January 24, 2013

Location: Southwest Oncology Group, San Antonio, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT00039182

Was this article helpful?
Dislike 0